Sprout Pharms patents expiration

1. Addyi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7420057 SPROUT PHARMS Stable polymorph of flibanserin
Aug, 2022

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468639 SPROUT PHARMS Treating sexual desire disorders with flibanserin
Oct, 2022

(11 months ago)

US8227471 SPROUT PHARMS Treating sexual desire disorders with flibanserin
May, 2023

(4 months ago)

US7151103 SPROUT PHARMS Method of treating female hypoactive sexual desire disorder with flibanserin
May, 2028

(4 years from now)

Drugs and Companies using FLIBANSERIN ingredient

Market Authorisation Date: 18 August, 2015

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)


More Information on Dosage

ADDYI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic